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Background: This study aimed to report the clinical and outcome data from a large cohort of patients diagnosed
with acromegaly and treated at our institution over a 20-year period.
Methods: Sixty-two acromegaly patients (32 women and 30 men) treated and monitored at the endocrinology
polyclinic between 1984 and 2013 were enrolled in this retrospective study. Clinical features and patients’ treatment
outcomes were evaluated. A level of growth hormone (GH) of <2.5 ng/ml was considered as the criterion for
remission, and the normal insulin-like growth factor (IGF) range was based on gender and age.
Results: The mean age at the time of diagnosis was 38.8 ± 1.4 years, the time to diagnosis was 4.5 ± 0.3 years, and
the follow-up duration was 7.3 ± 0.8 years. Among patients’ symptoms, growth in hands and feet and typical facial
dysmorphism were the most prominent (92%). The number of patients with diabetes mellitus, hypertension and
hyperprolactinemia were 22 (35%), 13 (21%) and 13 (21%), respectively. Microadenomas and macroadenomas were
found in eight and 54 patients, respectively. A significant correlation was found between the initial tumor diameters
and GH levels (p = 0.002). The mean GH and IGF-1 levels were 39.18 ± 6.1 ng/ml and 993.5 ± 79 ng/ml, respectively.
Visual field defect was found in 16 patients (32%). Thirty-one patients were treated by transsphenoidal surgery. Four of
these were cured, 10 patients developed postoperative anterior pituitary hormone deficiency, and one patient
developed diabetes insipidus. Twenty patients were treated by transcranial surgery, of which two were cured,
while 17 patients developed postoperative anterior pituitary hormone deficiency. In total, five of the patients who
were not cured after surgery were given conventional radiotherapy, of which two were cured. Four of 15 patients,
on whom Gamma Knife radiosurgery was performed, were cured. Biochemical remission was achieved in 32 of 52
patients who received octreotide treatment, and in two of five patients who received lanreotide treatment.
Conclusions: The rate of surgical success in our patients was found to be low. This could be explained by an
absence of experienced pituitary surgical centers or surgeons in our region, and the fact that most patients
presented late at the macroadenoma stage.
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Acromegaly is a rare condition with a prevalence of
around 60 in 1,000,000 [1]. The cause in most patients is
a pituitary adenoma that produces growth hormone
(GH). Serum insulin-like growth factor 1 (IGF-1) con-
centration increases when its production is stimulated
by GH over-secretion. The clinical features of the disease* Correspondence: mehtap.evran@hotmail.com
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unless otherwise stated.occur because of the peripheral effects of excessive GH
and IGF-1, as well as tumor pressure. Diagnosis is made
based on increased serum basal GH level, an IGF-1 level
higher than normal limits for gender and age, and an
absence of suppression in serum GH levels (>1.0 ng/ml)
by the oral glucose tolerance test (OGTT). In acromegaly,
progressive deformations occur in the body, especially
in the face and extremities, the severity of which are as-
sociated with the time to diagnosis. The condition may
also cause other morbidities such as arterial hypertension,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DM), menstrual irregularities, arthropathy, and peripheral
neuropathy. Sometimes acromegaly occurs together with
hyperprolactinemia [2]. The risk of malignancy, particu-
larly colon cancer, is increased in acromegalic patients
[3,4]. The first treatment option for acromegaly is removal
of the pituitary adenoma by an experienced surgeon at
a specialist center for pituitary surgery. If surgery is
unsuccessful, treatment using somatostatin analogs (SA),
dopamine agonists, GH antagonist and/or Gamma Knife
radiosurgery can be used [5]. For the disease to be consid-
ered under control, the basal GH level should be <2.5 ng/ml,
GH levels should be <1.0 ng/ml by the OGTT, and the
IGF-1 levels should be within normal limits based on the
patient’s age and gender [6,7].
In this study, we report the clinical and outcome data
from a large cohort of acromegalic patients who were




Sixty-two acromegaly patients (32 women and 30 men)
diagnosed, treated and monitored at our endocrinology
polyclinic between 1984 and 2013 were enrolled in this
retrospective study. The files of the patients diagnosed
before 2007 were reviewed, and their details were evaluated.
Patients diagnosed after 2007 were included in the 62
patients and were followed prospectively in this study. In
addition to the demographics of the patients, we reviewed
time to diagnosis, age at the time of diagnosis, clinical
examination findings, assessment of field of vision, follow-
up time, treatment approach (surgical, radiotherapy, drug
treatment and/or their combination) and the outcomes of
these treatments. Postoperative pituitary hormone defi-
ciency, tumor diameter, serum GH and IGF-1 levels based
on age and gender, and GH response to oral glucose chal-
lenge were assessed. IGF-1 levels could not be measured
before 2001 at our center; consequently, 21 of our patients
did not have IGF-1 levels available at the time of diagnosis.
This paper is undertaken in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments. The local ethical committee of
Cukurova University approved the study.
Hormone assays
A chemiluminescence immunoassay was used to measure
patients’ serum GH and IGF-1 levels (Immulite 2000,
Siemens; ng/ml), and prolactin levels (DxI 800, Beckman
Coulter; ng/ml). For imaging of the pituitary gland, pituit-
ary CT was used in 10 patients, and pituitary MRI was
used in 52 patients.
In our study, biochemical remission was defined as a
basal GH <2.5 ng/ml, post-OGTT GH <1 ng/ml and IGF-1 level within normal limits based on age and gender [8].
Cases that showed permanent remission after a successful
surgery or radiotherapy (conventional radiotherapy or
Gamma Knife) were considered cured.
Statistical analysis
Statistical analyses using the Shapiro–Wilk, Mann–
Whitney U and Chi-squared tests were performed. For
correlations between the groups, the Pearson correlation
was used for the parameters that fitted normal distribu-
tion, and Spearman’s tests were used for the parameters
that did not the fit normal distribution. The results were
expressed as n (%) and SE ±mean and a p value of less
than 0.05 was considered significant. SPSS-19 software
was used for all statistical analyses.
Results
Characteristics of patients
Demographic and clinical characteristics of the patients
are shown in Table 1. The most common symptoms,
seen in 55/62 (92%) of patients, were transversal growth-
thickening in hands and feet and facial dysmorphism
(such as prominent forehead, separation of teeth, prog-
nathism, and growth of cartilage). Additionally, hyper-
prolactinemia was found in 13/62 patients at the time of
diagnosis, with four of these patients also presenting
with galactorrhea. Visual field defect was found in 16/50
patients who underwent visual field examinations. The
most common conditions that coexisted with acromegaly
in patients were DM (35%) and hypertension (21%).
Laboratory and imaging findings of patients
Patients’ GH and IGF-1 levels before treatment are
shown in Table 1 and Figure 1. The patients’ pituitary
CT/MRI images revealed microadenomas (<10 mm) in
eight patients, and macroadenomas (>10 mm) in 54/62
(86%) patients. The tumor diameter of the patients with
macroadenomas was 10–20 mm in 16 patients (25.8%),
and >20 mm in 31 patients (50%). Cavernous sinuous
invasion was found in 25 patients. There was a signifi-
cant correlation between the initial tumor diameters and
preoperative GH levels (p = 0.002).
Surgical treatment methods and outcomes
Treatment methods and outcomes are summarized in
Table 2. Thirty-four patients underwent surgery in our
center performed by one of two surgeons, six patients
underwent surgery in another center performed by the
same surgeon, four patients underwent surgery in different
centers by the same surgeon and the remaining 12 patients
underwent surgery in four other centers performed by
different surgeons. Thirty-one patients (50%) underwent
transsphenoidal surgery, with four attaining postoperative
cure. Three of these latter patients had microadenoma,
Table 1 Demographic and clinical characteristics of acromegaly patients at the time of diagnosis
SE ±mean (Range) n (%)
Age (years) 46.2 ± 1.4 (18–75) Number of microadenomas 8/62 (13%)
Age at the time of diagnosis (years) 38.2 ± 1.4 (8–65) Number of macroadenomas 54/62 (87%)
Time to diagnosis (years) 4.5 ± 0.3 (1–14) Hyperprolactinemia 13/62 (21%)
Follow-up duration 7.3 ± 0.8 (1–29) Hypertension 13/62 (21%)
GH level (ng/ml); (n = 54) 39.18 (2.1–179) Diabetes Mellitus 22/62 (35%)
#IGF-1 level (ng/ml); (n = 41) 993.5 ± 79 (262–3000) Carpal Tunnel Syndrome 2/62 (3.2%)
IGF-1 level (n = 1)* 1700 ± 0 Menstrual irregularity 4/32 (12.5%)
IGF-1 levels (n = 4)** 1318 ± 788 Loss of libido 2/62 (3.2%)
IGF-1 levels (n = 17)*** 770.5 ± 694 Galactorrhea 4/62 (6.5%)
IGF-1 levels (n = 19)**** 1078 ± 1249 Headache 4/62 (6.5%)
Typical facial findings and growth in hands and feet 55/62 (92%)
#IGF-1 levels (based on age and gender).
*Male, for 6–8 years; normal range of IGF-1: 110-565 ng/ml.
**Female and male, for 16–25years; normal range of IGF-1: 182-780 ng/ml.
***Female, for > 25 years; normal range of IGF-1: 123-463 ng/ml.
****Male, for > 25 years; normal range of IGF-1: 123-463 ng/ml.
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underwent transcranial surgery attained postoperative cure.
One of these had macroadenoma, and one had microade-
noma. Four of the patients who did not attain cure after
transsphenoidal surgery underwent transcranial surgery
again. None of these patients attained postoperative cure
after the second surgery. Within the patients who could
not be cured following pituitary surgery, eight underwent
surgery a second time, two received surgery three times
and one seven times.Pituitary deficiency rates
Pituitary hormones were evaluated prior to transsphenoi-
dal surgery in only one patient, which revealed evidence
of preoperative pituitary hormone deficiency in this pa-
tient. The other 61 patients were evaluated postoperatively
only. In the postoperative period, one or more anterior
pituitary hormone deficiencies were found in 10 patients,Figure 1 Before and after treatment IGF-1 levels of the patients (norm
normal range of IGF-1: 110-565 ng/ml (n = 1), **Female and Male; normal r
remission:3) ***Female; normal range of IGF-1: 123-463 ng/ml (prereatment
IGF-1: 123-463 ng/ml (pretreatment n:19, posttreatment n:23; remission:13).and permanent diabetes insipidus (DI) was found in one
patient. One patient, who underwent transcranial surgery
after transsphenoidal surgery, developed hypothyroidism.
In the 17 patients who underwent transcranial surgery,
one or more anterior pituitary hormone deficiencies
were detected during the postoperative period.Outcomes of radiotherapy and gamma knife radiosurgery
Conventional radiotherapy was performed on only five
patients, two of whom attained cure (their durations to
cure were 5 and 10 years). These five patients also received
postoperative octreotide treatment. Four of the 15 patients
who received Gamma Knife treatment attained cure (the
duration to cure was 5 years for two patients, 4 years for
one patient, and 3 years for one patient). Seven of the
remaining 11 patients achieved biochemical remission with
postoperative octreotide treatment. Further treatment of
the patients who did not enter remission is ongoing.al range is given according to age and gender). # y: years *Male;
ange of IGF-1: 182-780 ng/ml (pretreatment n: 4, posttreatment n:5;
n:17, posttreatment n:26; remission:21) **** Male; normal range of
Table 2 Rate of treatment response for different disease






n (%) n (%)
Microadenomas 8 (13%) 4 (50%)
Macroadenomas 54 (87%) 8 (15%)
Transsphenoidal surgery 31 (52%) 4 (12.9%)
Transcranial surgery 20 (32.3%) 2 (10%)
Multiple surgery 11 (17.7%)
Radiotherapy 20 (32.2%) 6 (30%)*
Only drug treatment 6 (9.6%) 3 (50%)**
Octreotide LAR 52 (84%) 32 (61.5%)**
Lanreotide 5 (8%) 2 (40%)**
Conventional radiotherapy +
ocreotide LAR
5 (8%) 2 (40%)**
Gamma Knife + ocreotide LAR 11 (17.7%) 7 (63%)**
*The number of patients who achieved cure by Gamma Knife and
conventional radiotherapy.
**Biochemical remission.
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SA treatment without surgery was administered in six
patients owing to the lack of eligibility or consent for
surgery. Four of these patients received primary octreotide
LAR, while the remaining two were given primary lanreo-
tide. The treatment dose of octreotide was 20–30 mg/
month, and normalization was achieved in serum GH and
IGF-1 levels in three of the four patients. The biochemical
remission durations with medication of these three pa-
tients were 6, 8 and 11 years, respectively. No remission
could be achieved in two patients who received primary
lanreotide treatment (90–120 mg/month).
Forty-eight of the 62 patients who did not achieve
postoperative success were given octreotide LAR treat-
ment, and 29 of these 48 patients (60.2%) achieved
remission. Likewise, a further three patients who did not
achieve postoperative success were given lanreotide
treatment and two of these (66.6%) achieved remission.
The drug dose was increased to 120 mg for these
patients (Figure 2). In total, 32 of the 52 patients (61.5%)Figure 2 According to pharmacotherapy remission rates of the patienwho were given octreotide treatment, and two of the five
patients (40%) who were given lanreotide treatment,
achieved GH levels of <2.5 ng/ml, and IGF-1 levels
within normal limits based on age (Figure 1).
Tumor reduction
In two of the four patients who received octreotide treat-
ment without surgery, the tumor diameter did not
change (3- and 8-year follow-ups, respectively). In the
other two patients, a reduction in tumor diameter was
detected (from 8 to 7 mm after 6 years and from 15 to
12 mm after 12 years, respectively). In one of the two
patients who received 60 mg/month of lanreotide treat-
ment without surgery, a marked reduction in tumor
diameter was observed after 6 months (from 33 to
20 mm), while in the other patient, a smaller reduction
was observed after 1 year (from 11 to 9 mm).
Of the 32 patients in whom a reduction in tumor size
was observed, only 20 achieved biochemical remission.
Indeed, there was no significant relationship between
tumor diameter and achievement of cure (p = 0.06). Inter-
estingly, anterior pituitary hormone deficiency was found
in three of eight patients with microadenoma (37.5%) and
in 25 of 54 patients with macroadenoma (46.3%); this
difference was statistically significant (p = 0.005; Table 3).
Discussion
Our study has made it possible to review the most
important findings and challenges in managing a large
cohort of acromegaly patients over a 20-year period.
Although acromegaly can be seen in all ages, the aver-
age age of onset is 32 years. However, as it progresses
subclinically, the diagnosis is delayed by between 4 and
10 years [1,2]. This duration has decreased recently, for
example, in a study of 100 patients, the delay in diagno-
sis was found to be 3.2 years [9]. More frequent MRI
performed for different reasons may be one explanation
for earlier incidental diagnosis of acromegaly [10]. In
our patients, the age average at the time of diagnosis
was found to be 38.8 ± 1.4 years, and the time to diagnosis
was found to be 4.5 ± 0.3 years.
The typical features of acromegaly develop over time,
and their severity is associated with a patient’s age, GHts.
Table 3 Frequency of pituitary hormone deficiency in the
postoperative period by disease subtype
Deficient hormones Microadenomas (n) Macroadenomas (n)
TSH 8
ACTH 2
TSH + ACTH 6
FSH + LH 3
TSH + ACTH + FSH + LH 6
TSH + FSH + LH 1 2
ADH 1
Total* 4 25
*Transsphenoidal: Anterior pituitary hormone deficiency in 10 patients, and DI
in one patient.
TSH deficiency in one patient who underwent transcranial surgery after
transsphenoidal surgery.
Transcranial: Anterior pituitary hormone deficiency in 17 patients.
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Indeed the delay in diagnosis can be explained, in part,
by the fact that any facial changes are often attributed to
aging; old photographs of the patient are therefore a
useful diagnostic tool. Skeletal and soft tissue changes,
organomegaly and typical facial changes are also com-
mon [11]. The most common symptoms of our patients,
seen in 92%, were growth in hands and feet, and facial
dysmorphism. Additionally, acromegaly patients have an
increased incidence of DM, hypertension, cardiovascular
diseases, breathing problems, osteoporosis and osteoarticu-
lar dysfunctions compared with the normal population.
The incidence of glucose intolerance is 16–46%, and the
incidence of DM is 19–56% [12,13]. The anti-insulinergic
effects of GH are considered to be responsible for the
pathogenesis of acromegaly. In many cases, when acromeg-
aly is cured, DM is also cured [14]. The most common
conditions that coexisted with acromegaly in our patients
were DM (35%) and hypertension (20.9%), in keeping with
the literature.
The incidence of hyperprolactinemia in pituitary acro-
megaly patients is approximately 30–40%. The reasons
for hyperprolactinemia are pressure on the pituitary
stalk or simultaneous secretion of prolactin from tumor
cells [15-17]. Incidence of simultaneous secretion of GH
and prolactin is around 25% [18]. In our cohort, 13
patients (21%) were found to have hyperprolactinemia at
the time of diagnosis, a significantly higher rate than
that described in the study by Moyes et al. (13%) [19].
Around 40% of patients are diagnosed in clinics other
than endocrinology for symptoms and findings of in-
creased cranial pressure. For instance, neurological
symptoms and vision problems may occur because of
growth of a pituitary adenoma [11]. The incidence of
visual field defect owing to increased pressure is around
19–20% in the literature [20]. The rate of visual fielddefect in our patients was 32%. In keeping with the pub-
lished literature, imaging detected macroadenomas in 54
of our patients (87%) [7,21].
In acromegaly, serum basal GH measurement, post-
OGTT GH measurement and IGF-I levels measurement
are the gold standard assays for measuring disease activity
and monitoring the effectiveness of treatment. While GH
measurement has become more sensitive in the recent
decades, IGF-1 measurements can be misleading in situa-
tions such as malnutrition, liver disease and kidney failure
[22,23]. In particular, inconsistencies between GH and
IGF-1 measurements can be seen throughout SA treat-
ment [17]. Our patients usually showed a positive correl-
ation between the average GH levels and IGF-1 levels at
the time of diagnosis and during SA treatment.
The first treatment option in acromegaly is transsphe-
noidal tumor excision, particularly for intrasellar microa-
denomas and noninvasive macroadenomas. In situations
such as patient non-consent, existence of serious cardiomy-
opathy and respiratory disease or absence of an experienced
surgeon, then other treatment options are considered. The
finding of visual field defect or neurological deficit is almost
always an urgent surgical indication [24,25]. We also apply
transsphenoidal surgery as the first treatment option for
many of our patients.
In a previous retrospective study of 100 patients who
underwent transsphenoidal surgery with a remission cri-
terion of GH <5 mU/l, 42% of the patients achieved
postoperative remission. In this study, the remission rates
were associated with tumor diameter and preoperative
GH levels, and 21 patients were found to have pituitary
hormone deficiency [26]. The postoperative cure rate of
patients who underwent transsphenoidal surgery was
12.9%. In studies where remission criteria were considered
to be either GH <2.5 ng/ml, post-OGTT GH <2 ng/ml or
IGF-1 within normal limits based on age and gender,
the remission rates after transsphenoidal surgery were
found to be 38, 57 and 37%, respectively, and the anterior
pituitary hormone deficiency rates were found to be 35, 8
and 10%, respectively [7,27,28]. Currently, the reported suc-
cess of intrasellar surgery varies between 75 and 95% for
intrasellar microadenomas, and between 45 and 68% for
noninvasive macroadenomas, if undertaken by experienced
surgeons who perform at least 50 case surgeries per year
[24,29]. When our patients were evaluated, four of 31
patients who were operated transsphenoidally attained
postoperative cure. Three of these patients had microa-
denoma, and one had macroadenoma. While anterior
pituitary hormone deficiency was found only in one
patient before surgery, it was found in 37% of the patients
after surgery. The rate of post-operative pituitary hormone
deficiency was found to be lower in our cohort compared
with the study by Sheaves et al., but higher than that
observed by Swearingan et al. [26,27].
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noidal surgery, a transcranial approach is required in
some situations such as suprasellar tumor expansion. In
another study with remission criteria similar to ours with
a follow-up period of 19 years, 26 of 668 acromegaly
patients underwent transcranial surgery. The postopera-
tive remission rate of these was 7.7%, the anterior pituitary
hormone deficiency rate was 5%, and the rate of per-
manent DI was 11.5%. In the latter series, 140 patients
were re-operated, and the remission rate increased to
27.1% [30]. In our study, two of the 20 patients who
were operated on transcranially attained postoperative
cure, one of whom had macroadenoma and the other
microadenoma. In the patients who did not achieve
cure after transsphenoidal surgery and then underwent
transcranial surgery, none attained cure, with only one
developing secondary hypothyroidism. Although our data
on pituitary hormone deficiency before transcranial surgery
was insufficient, the rate of patients with anterior pituitary
hormone deficiency after transcranial surgery was 85%,
a markedly higher rate compared with similar published
cohorts. Additionally, the rate of anterior pituitary hormone
deficiency in our patients who underwent transcranial
surgery was significantly higher than in the patients who
underwent transsphenoidal surgery (p < 0.001).
The success of treatment in acromegaly is negatively
correlated with tumor diameter and basal GH levels and
positively correlated with the experience of the surgeon.
Additionally, if the tumor is invasive, this decreases the
likelihood of successful surgery [24,31]. Indeed, when we
assessed our results based on tumor size, 50% of those with
microadenoma and 15% of those with macroadenoma were
cured. Unfortunately, owing to small sample numbers,
assessment of significance was not feasible. Precise tumor
diameter was significantly associated with GH level
(p = 0.002), but did not correlate with cure rate (p = 0.06).
Additionally, only 20 of 32 patients whose tumor diame-
ters reduced developed biochemical remission. Twenty-
five of our patients also had cavernous sinuous invasion.
Another important factor that affects success rate is
the number of surgeons who can perform this surgery,
and the number of pituitary surgeries performed by the
surgeons. Additionally, a greater number of years of sur-
gical experience also increases the surgical success rate
[25]. Our cure rate after transsphenoidal and transcra-
nial surgery was very low compared with the literature.
More than half of our patients (n = 34) were operated on
in our center by one of two surgeons while the others
were operated on in several external centers. The lack of
experience of our surgeons in pituitary surgery, the
absence of a single specialist operating center and the
existence of macroadenoma or cavernous sinuous invasion
at the time of diagnosis are therefore likely contributors to
our low surgical success rate.Radiotherapy is preferred in situations where surgery is
contraindicated or unsuccessful, or when medical treat-
ment is insufficient in controlling GH secretion [32]. An
average of 60% of patients who receive conventional
radiotherapy attain GH and IGF-1 normalization, but the
maximum response is seen after 10–15 years [24,33].
While conventional radiotherapy is preferred in large
recidive tumors or in tumors close to the optical nerve,
Gamma Knife radiosurgery is preferred in smaller tumors.
The 5-year remission rates following Gamma Knife is
between 29 and 60% [34]. The incidence of pituitary defi-
ciency for both methods is similar [28,31]. Some of our
patients who did not achieve cure after surgery received
radiotherapy. Thirty percent of the patients who received
conventional radiotherapy or Gamma Knife attained cure,
and a further 50% entered biochemical remission. The time
to cure was 5–10 years for the two patients who received
conventional radiotherapy, and 3–5 years in the four
patients who received Gamma Knife. Thus, our rate of
cure with surgical treatment and radiotherapy was 19.3%
(12 patients), which is in keeping with the literature.
It has been shown in vitro that natural somatostatin
inhibits GH secretion in many GH-secreting tumors.
For this reason, SAs have been developed for treating
acromegaly. Somatostatin analogs work by activating
somatostatin receptors. There are, however, major gastro-
intestinal side effects associated with these drugs. Long-
lasting forms of somatostatin analogs are preferred, and
octreotide LAR and lanreotide autogel are in current
clinical use in Turkey, but not pasireotide. Pegvisomant
is a GH receptor antagonist, which can be used alone
or in combination with SAs [17]. Somatostatin analogs
can be used for situations when there is little possibility
of surgical cure such as large extrasellar tumors without
pressure effect, in patients who cannot be controlled
biochemically with surgery, and to provide biochemical
control while waiting for the effect of radiotherapy.
Although there are data that show that preoperative SA
use has benefits on GH and IGF-1 normalization and on
postoperative hospitalization, some studies have concluded
that it does not [24,35]. Some studies have shown that with
use of somatostatin analogs, biochemical remission is
attained, and tumors become smaller in size [36,37].
Several long-term retrospective studies have reviewed
the effects of SA given postoperatively and/or primarily,
and have reported a wide variation of biochemical remis-
sion rates of between 34 and 95% [38,39]. Investigations
comparing efficacy of lanreotide and octreotide treatments
have reported a similar rate of cure of symptoms and
biochemical cure for both agents [40-42].
It should be kept in mind that our study is not a study
for evaluating response to primary SA treatment. In our
study, we used serum GH <2.5 ng/ml and IGF-1 normal-
ization as biochemical remission criterion, and the serum
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treatment decreased significantly compared with the base-
line (p < 0.001). When we review all our patients with
regards to biochemical remission, we see that 32/52
patients (61.5%) who received octreotide treatment and
2/5 patients (40%) who received lanreotide treatment
are in biochemical remission. However, it should be
noted that 10 of the patients who achieved biochemical
remission received Gamma Knife, and five received con-
ventional radiotherapy; therefore, the cause of remission
may be multifactorial in these patients.
In a recent study by Coloa et al., which followed up 45
acromegalic patients, no improvement in glucose intoler-
ance or DM prevalence was seen [37]. However, we
observed improvement in DM in four of the 22 patients in
our cohort who were initially diagnosed with DM. Two of
these patients, whose blood glucose levels improved were
in remission and one of them was cured.
A notable restriction of our study was that the file
archiving system was more irregular and insufficient in
previous years, and therefore we did not have access to a
full range of data for all patients. For example, the initial
IGF-1 level was the most important predictor of adequate
response to treatment [43]; however, this measurement
was not available for some patients. Furthermore, we did
not have access to data concerning presence or absence of
pituitary hormone deficiency before treatment. Addition-
ally, the majority of our patients were operated on in
different centers by different surgeons and some patients
did not attend our hospital for assessment with optimum
regularity. Indeed, infrequent monitoring may be an
additional contributing factor to the low rate of cure in
our cohort compared with the literature.
In conclusion, we believe the rate of successful treat-
ment of acromegaly will increase with earlier diagnosis,
greater surgical experience and regular and appropriate
follow-up after surgery. Future prospective studies of
large cohorts will help to provide further information
on appropriate treatment strategies in this disease.Competing interests
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